Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th
Back

Canadian Cannabis Stocks Trade Higher On Earnings

Aug 15, 2017 • 10:41 AM EDT
TRTC (14).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Earnings season has started to heat up for marijuana stocks and we have seen several companies report earnings that have shown significant growth.

We have also seen companies report earnings that have completely missed the mark.

Today, we are going to highlight three marijuana stocks have recently reported earnings and will provide updates on these companies.

Canopy Growth Continues to Lead

Leading Canadian marijuana producer Canopy Growth Corp. (WEED.TO) (TWMJF) traded slightly higher after the company released its first quarter financial results yesterday and we continue to view the firm as one of the best long-term cannabis investment opportunities.

Canopy generated almost $16 million in revenue during the quarter and continues to record strong top-line growth. The marijuana producer is the largest is Canada and is also focused on medical marijuana market in Germany, Australia, and Chile.

As of June 30th, Canopy Growth reported to have $115.5 million in cash and cash equivalents. The company is well capitalized, well positioned, and well managed. We expect Canopy to continue to lead the global marijuana movement and believe this is an opportunity that cannot be ignored.

Read the full earnings report HERE.

Surna Earnings Miss The Mark

Colorado-based ancillary cannabis company, Surna (SRNA) reported second quarter earnings yesterday that missed the mark and we remain cautious with the company after this report.

Although Surna sells an ancillary product for cultivators, the company blamed the weaker results on the fear created by the Trump administration. We think this excuse is not valid since the company can easily focus on selling its product in other international markets.

The earnings reported was prepared on a going concern basis and management said the cash balance and cash flow from operations will not be sufficient to fund operations over the next twelve months.

As of June 30th, Surna had an accumulated deficit of $16,410,000, a $778,000 deficit in working capital, and $1,353,000 in cash. We are cautious with the shares at current levels and will continue to monitor how this situation develops.

MedReleaf Trades Higher on Sound Earnings

MedReleaf (LEAF.TO) (MEDFF) received a favorable response from the market after the Canadian licensed medical marijuana producer released its first quarter financial results.

Cannabis oils have become a major market in the Canadian cannabis industry and we have been watching this trend on an industry and company level. MedReleaf has benefited from a trend toward smokeless products after it was approved to start selling cannabis oils in the third quarter of 2017.

During the most recent quarter, cannabis-based extract products accounted for 14% of MedReleaf’s total revenue. We expect this number to trend higher over the next year and approach the 50% level. 

Although revenue increased by almost 20% when compared to the prior quarter, net income was $2.9 million lower. The lower net income was primarily due to increased operating costs and the main driver of these higher costs was IPO related expenses, which amounted to $2.5 million.

We remain favorable on MedReleaf and continue to view it as a stock that investors need to watch. 

Read the full earnings report HERE.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link